Abstract AIM: Triple-negative breast cancer has a poor prognosis due to its aggressive behaviour and lack of effective targeted therapies. We aimed to verify whether clinical and/or pathological features may help us identify triple-negative breast cancer with a different outcome. PATIENTS AND METHODS: Patients diagnosed with stage I-III triple-negative breast cancer at our Institution were included in the analysis. The impact of various factors (age, menopausal status, tumor characteristics, adjuvant treatment, etc.) on survival was evaluated. Univariate and multivariate analyses were performed. RESULTS: A total of 149 patients were included in this retrospective analysis. At univariate analysis, a better disease-free survival was related to smaller tumour size and absence of lymphovascular involvement or necrosis. At multivariate analysis, tumour size and lympho-vascular invasion were independent prognostic factors. CONCLUSION: Triple-negative breast cancer represents a heterogeneous disease with different biology and clinical behaviour. These results re-inforce the wide use of adjuvant chemotherapy for all types of triple-negative breast cancer, regardless of tumour size or lymphovascular invasion. New biomarkers are mandatory for a better stratification of this heterogeneous population.

Prognostic factors in early-stage triple-negative breast cancer: lessons and limits from clinical practice / Pistelli, M.; Pagliacci, A.; Battelli, N.; Santinelli, A.; Biscotti, T.; Ballatore, Z.; Berardi, R.; Cascinu, Stefano. - In: ANTICANCER RESEARCH. - ISSN 0250-7005. - 33:6(2013), pp. 2737-2742.

Prognostic factors in early-stage triple-negative breast cancer: lessons and limits from clinical practice.

CASCINU, Stefano
2013

Abstract

Abstract AIM: Triple-negative breast cancer has a poor prognosis due to its aggressive behaviour and lack of effective targeted therapies. We aimed to verify whether clinical and/or pathological features may help us identify triple-negative breast cancer with a different outcome. PATIENTS AND METHODS: Patients diagnosed with stage I-III triple-negative breast cancer at our Institution were included in the analysis. The impact of various factors (age, menopausal status, tumor characteristics, adjuvant treatment, etc.) on survival was evaluated. Univariate and multivariate analyses were performed. RESULTS: A total of 149 patients were included in this retrospective analysis. At univariate analysis, a better disease-free survival was related to smaller tumour size and absence of lymphovascular involvement or necrosis. At multivariate analysis, tumour size and lympho-vascular invasion were independent prognostic factors. CONCLUSION: Triple-negative breast cancer represents a heterogeneous disease with different biology and clinical behaviour. These results re-inforce the wide use of adjuvant chemotherapy for all types of triple-negative breast cancer, regardless of tumour size or lymphovascular invasion. New biomarkers are mandatory for a better stratification of this heterogeneous population.
33
6
2737
2742
Prognostic factors in early-stage triple-negative breast cancer: lessons and limits from clinical practice / Pistelli, M.; Pagliacci, A.; Battelli, N.; Santinelli, A.; Biscotti, T.; Ballatore, Z.; Berardi, R.; Cascinu, Stefano. - In: ANTICANCER RESEARCH. - ISSN 0250-7005. - 33:6(2013), pp. 2737-2742.
Pistelli, M.; Pagliacci, A.; Battelli, N.; Santinelli, A.; Biscotti, T.; Ballatore, Z.; Berardi, R.; Cascinu, Stefano
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1079129
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 25
  • ???jsp.display-item.citation.isi??? 24
social impact